Univariate regression model for overall mortality
| Variable . | Group . | HR . | 95% CI . | P . | Global P . |
|---|---|---|---|---|---|
| Marrow myeloblasts* | 1.02 | 1.01-1.02 | < .0001 | ||
| Hemoglobin* | 0.95 | 0.90-1.01 | .08 | ||
| Platelet count* | 0.93 | 0.90-0.97 | .0005 | ||
| Patient age* | 1.07 | 1.02-1.12 | .005 | ||
| Disease category | MDS | 1 | |||
| tAML | 1.57 | 1.34-1.86 | < .0001 | ||
| IPSS cytogenetic risk | Good | 1 | < .0001 | ||
| Intermediate | 1.16 | 0.93-1.45 | .19 | ||
| Poor | 1.77 | 1.47-2.12 | < .0001 | ||
| 5-group cytogenetic risk | Good | 1 | < .0001 | ||
| Very good | 1.15 | 0.57-2.32 | .71 | ||
| Intermediate | 1.13 | 0.90-1.43 | .28 | ||
| Poor | 1.29 | 1.01-1.63 | .04 | ||
| Very poor | 3.08 | 2.40-3.94 | < .0001 | ||
| Data incomplete | 1.88 | 1.50-2.36 | < .0001 | ||
| Donor type | Matched sibling | 1 | .01 | ||
| Nonsibling relative | 1.40 | 1.06-1.85 | .02 | ||
| URD matched | 0.88 | 0.72-1.07 | .19 | ||
| URD mismatched | 1.22 | 0.98-1.52 | .07 | ||
| URD unknown§ | 0.89 | 0.57-1.40 | .61 | ||
| Year of HCT* | 0.97 | 0.96-0.99 | < .0001 | ||
| Monosomal karyotype | No | 1 | |||
| Yes | 2.44 | 2.01-2.96 | < .0001 | ||
| Secondary MDS | No | 1 | |||
| Yes | 1.33 | 1.11-1.58 | .002 | ||
| Conditioning regimen† | BU + CY (± ATG) | 1 | < .0001 | ||
| FLU + LD TBI | 1.49 | 1.14-1.96 | .004 | ||
| BU + TBI (12 Gy) | 2.21 | 1.65-2.95 | < .0001 | ||
| FLU + BU | 1.46 | 1.01-2.10 | .04 | ||
| BU + CY + TBI (12 Gy) | 1.86 | 1.30-2.67 | .0007 | ||
| 131I + FLU + TBI (2 Gy) | 1.86 | 1.15-3.00 | .01 | ||
| FLU + TREO | 0.43 | 0.18-1.04 | .06 | ||
| CY + TBI (≥ 12 Gy) (± ATG) | 1.66 | 1.35-2.03 | < .0001 | ||
| Other | 1.69 | 1.11-2.57 | .01 | ||
| FAB/WHO classification | RA/RARS/RCMD | 1 | < .0001 | ||
| RAEB | 1.63 | 1.36-1.96 | < .0001 | ||
| RAEB-T | 2.02 | 1.56-2.63 | < .0001 | ||
| tAML | 2.37 | 1.86-3.02 | < .0001 | ||
| Etiology‡ | de novo | 1 | < .0001 | ||
| MPN | 2.36 | 1.17-4.75 | .03 | ||
| Lymphoma | 1.50 | 1.11-2.02 | .008 | ||
| Multiple myeloma | 3.12 | 1.29-7.55 | .01 | ||
| Autoimmune disorders | 1.76 | 1.08-2.85 | .02 | ||
| Organ transplant | 2.64 | 0.85-8.22 | .09 | ||
| Accidental radiation exposure | 11.4 | 2.83-46.1 | .0006 | ||
| Treatment pre-HCT | No | 1 | .01 | ||
| IC | 1.27 | 1.08-1.50 | .004 | ||
| IC + hypomethylation | 0.51 | 0.07-3.63 | .50 | ||
| Hypomethylation | 0.84 | 0.53-1.34 | .47 |
| Variable . | Group . | HR . | 95% CI . | P . | Global P . |
|---|---|---|---|---|---|
| Marrow myeloblasts* | 1.02 | 1.01-1.02 | < .0001 | ||
| Hemoglobin* | 0.95 | 0.90-1.01 | .08 | ||
| Platelet count* | 0.93 | 0.90-0.97 | .0005 | ||
| Patient age* | 1.07 | 1.02-1.12 | .005 | ||
| Disease category | MDS | 1 | |||
| tAML | 1.57 | 1.34-1.86 | < .0001 | ||
| IPSS cytogenetic risk | Good | 1 | < .0001 | ||
| Intermediate | 1.16 | 0.93-1.45 | .19 | ||
| Poor | 1.77 | 1.47-2.12 | < .0001 | ||
| 5-group cytogenetic risk | Good | 1 | < .0001 | ||
| Very good | 1.15 | 0.57-2.32 | .71 | ||
| Intermediate | 1.13 | 0.90-1.43 | .28 | ||
| Poor | 1.29 | 1.01-1.63 | .04 | ||
| Very poor | 3.08 | 2.40-3.94 | < .0001 | ||
| Data incomplete | 1.88 | 1.50-2.36 | < .0001 | ||
| Donor type | Matched sibling | 1 | .01 | ||
| Nonsibling relative | 1.40 | 1.06-1.85 | .02 | ||
| URD matched | 0.88 | 0.72-1.07 | .19 | ||
| URD mismatched | 1.22 | 0.98-1.52 | .07 | ||
| URD unknown§ | 0.89 | 0.57-1.40 | .61 | ||
| Year of HCT* | 0.97 | 0.96-0.99 | < .0001 | ||
| Monosomal karyotype | No | 1 | |||
| Yes | 2.44 | 2.01-2.96 | < .0001 | ||
| Secondary MDS | No | 1 | |||
| Yes | 1.33 | 1.11-1.58 | .002 | ||
| Conditioning regimen† | BU + CY (± ATG) | 1 | < .0001 | ||
| FLU + LD TBI | 1.49 | 1.14-1.96 | .004 | ||
| BU + TBI (12 Gy) | 2.21 | 1.65-2.95 | < .0001 | ||
| FLU + BU | 1.46 | 1.01-2.10 | .04 | ||
| BU + CY + TBI (12 Gy) | 1.86 | 1.30-2.67 | .0007 | ||
| 131I + FLU + TBI (2 Gy) | 1.86 | 1.15-3.00 | .01 | ||
| FLU + TREO | 0.43 | 0.18-1.04 | .06 | ||
| CY + TBI (≥ 12 Gy) (± ATG) | 1.66 | 1.35-2.03 | < .0001 | ||
| Other | 1.69 | 1.11-2.57 | .01 | ||
| FAB/WHO classification | RA/RARS/RCMD | 1 | < .0001 | ||
| RAEB | 1.63 | 1.36-1.96 | < .0001 | ||
| RAEB-T | 2.02 | 1.56-2.63 | < .0001 | ||
| tAML | 2.37 | 1.86-3.02 | < .0001 | ||
| Etiology‡ | de novo | 1 | < .0001 | ||
| MPN | 2.36 | 1.17-4.75 | .03 | ||
| Lymphoma | 1.50 | 1.11-2.02 | .008 | ||
| Multiple myeloma | 3.12 | 1.29-7.55 | .01 | ||
| Autoimmune disorders | 1.76 | 1.08-2.85 | .02 | ||
| Organ transplant | 2.64 | 0.85-8.22 | .09 | ||
| Accidental radiation exposure | 11.4 | 2.83-46.1 | .0006 | ||
| Treatment pre-HCT | No | 1 | .01 | ||
| IC | 1.27 | 1.08-1.50 | .004 | ||
| IC + hypomethylation | 0.51 | 0.07-3.63 | .50 | ||
| Hypomethylation | 0.84 | 0.53-1.34 | .47 |
CMV status and source of stem cells had no significant impact on outcome.
URD indicates unrelated donor; ATG, antithymocyte globulin; LD, low-dose TBI (2-4.5 Gy); TREO, treosulfan; MPN, myeloproliferative neoplasm; and IC, induction chemotherapy.
Modeled as continuous linear variables (as specified in Table 5);
Other regimens used (CY + TMI; FLU + TBI + CY; CY + BU) did not result in a significant difference.
Other antecedent conditions (aplastic anemia; constitutional marrow failure syndromes; solid tumors; other leukemias) had no significant impact.
Allele level typing was not performed.